首页|微创等离子消融术在扁桃体腺样体肥大患者治疗中的应用及对其免疫能力及氧化应激水平的影响

微创等离子消融术在扁桃体腺样体肥大患者治疗中的应用及对其免疫能力及氧化应激水平的影响

扫码查看
目的 探讨微创等离子消融术在扁桃体腺样体肥大患者治疗中的应用效果及对其免疫能力及氧化应激水平的影响.方法 将100例扁桃体腺样体肥大患者随机分为两组各50例.对照组行扁桃体剥离术治疗,观察组行微创等离子消融术治疗.比较两组免疫功能、氧化应激指标与并发症风险.结果 术后1个月,观察组CD3+、CD4+、CD4+/CD8+高于对照组(P<0.05).术后,观察组SOD高于对照组,MDA低于对照组(P<0.05).观察组并发症发生率低于对照组(P<0.05).结论 微创等离子消融术在扁桃体腺样体肥大患者治疗中的应用效果较好,可加快患者术后免疫功能恢复,降低氧化应激风险和并发症发生率.
Application of Minimally Invasive Plasma Ablation in the Treatment of Patients with Tonsillar Adenoid Hypertrophy and the Impact on the Immune Function and Oxidative Stress Level
Objective To explore the application effect of minimally invasive plasma ablation in the treatment of patients with tonsillar adenoid hypertrophy and the impact on the immune function and oxidative stress level.Methods 100 patients with tonsillar adenoid hypertrophy were randomly divided into two groups equally.The control group was treated with tonsillectomy,while the observation group was treated with minimally invasive plasma ablation.The immune function,oxidative stress indicators,and risk of complications were compared between the two groups.Results 1 month after surgery,the CD3+,CD4+and CD4+/CD8+of the observation group were higher than those of the control group(P<0.05).After surgery,the SOD of the observation group was higher than that of the control group,while the MDA was lower than that of the control group(P<0.05).The incidence of complications in the observation group was 2.00%,lower than 14.00%in the control group(P<0.05).Conclusions Minimally invasive plasma ablation has better application effect in the treatment of patients with tonsillar adenoid hypertrophy,which can accelerate the recovery of postoperative immune function,reduce the risk of oxidative stress and the incidence of complications.

Minimally invasive plasma ablationTonsillar adenoid hypertrophyImmune functionOxidative stress

李世伟、田秀芬、窦倩雯

展开 >

郑州大学第一附属医院咽喉头颈外科,河南郑州 450052

微创等离子消融术 扁桃体腺样体肥大 免疫功能 氧化应激

2024

临床医学工程
国家医疗保健器具工程技术研究中心

临床医学工程

影响因子:0.193
ISSN:1674-4659
年,卷(期):2024.31(9)